Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease.
D000818:Animals; D001923:Brain Chemistry; D003913:Dextroamphetamine / Q000494:pharmacology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D010627:Phenethylamines / Q000008:administration & dosage*; D012642:Selegiline / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology; D013239:Stereotyped Behavior / Q000187:drug effects
D010627:Phenethylamines; D012642:Selegiline; D007980:Levodopa; D003913:Dextroamphetamine